{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:21:45Z","timestamp":1776673305387,"version":"3.51.2"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":5071,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2012]]},"DOI":"10.1186\/2110-5820-2-32","type":"journal-article","created":{"date-parts":[[2012,7,23]],"date-time":"2012-07-23T06:14:09Z","timestamp":1343024049000},"page":"32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review"],"prefix":"10.1016","volume":"2","author":[{"given":"Pedro","family":"P\u00f3voa","sequence":"first","affiliation":[]},{"given":"Jorge I F","family":"Salluh","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1186\/2110-5820-2-32_bb0010","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","article-title":"Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care","volume":"29","author":"Angus","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0015","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000","volume":"348","author":"Martin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1186\/2110-5820-2-32_bb0020","unstructured":"Agency for Healthcare Research and Quality: Diagnostic groups with rapidly increasing costs by payer. 2001\u20132007. HCUP statistical brief 91. http:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb91.pdf"},{"key":"10.1186\/2110-5820-2-32_bb0025","unstructured":"The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New ZealandCrit Care Resusc 2007, 9: 8\u201318."},{"key":"10.1186\/2110-5820-2-32_bb0030","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/CCM.0b013e3181958b1c","article-title":"Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study)","volume":"37","author":"Povoa","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00134-009-1738-3","article-title":"The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis","volume":"36","author":"Levy","year":"2010","journal-title":"Intensive Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0040","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1164\/rccm.200812-1912OC","article-title":"Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study","volume":"180","author":"Ferrer","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0045","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1164\/ajrccm.162.2.9909095","article-title":"Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription","volume":"162","author":"Singh","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0050","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201101-0037OC","article-title":"Prompting physicians to address a daily checklist and process of care and clinical outcomes: a single-site study","volume":"184","author":"Weiss","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0055","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/cc8155","article-title":"Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia","volume":"14","author":"Christ-Crain","year":"2010","journal-title":"Crit Care"},{"key":"10.1186\/2110-5820-2-32_bb0060","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/cc8872","article-title":"Sepsis biomarkers: a review","volume":"14","author":"Pierrakos","year":"2010","journal-title":"Crit Care"},{"key":"10.1186\/2110-5820-2-32_bb0065","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/QCO.0b013e3282f47c32","article-title":"Serum markers in community-acquired pneumonia and ventilator-associated pneumonia","volume":"21","author":"Povoa","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.1186\/2110-5820-2-32_bb0075","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1097\/01.CCM.0000065186.67848.3A","article-title":"Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25\u201326, 2000","volume":"31","author":"Marshall","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0080","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","article-title":"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial","volume":"290","author":"Chastre","year":"2003","journal-title":"JAMA"},{"key":"10.1186\/2110-5820-2-32_bb0085","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1378\/chest.125.5.1791","article-title":"A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia","volume":"125","author":"Micek","year":"2004","journal-title":"Chest"},{"key":"10.1186\/2110-5820-2-32_bb0090","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1186\/2110-5820-2-32_bb0095","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1186\/2110-5820-2-32_bb0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ageing\/26.2.153","article-title":"Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient","volume":"26","author":"Hogarth","year":"1997","journal-title":"Age Ageing"},{"key":"10.1186\/2110-5820-2-32_bb0105","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00006454-199708000-00003","article-title":"Clinical applications of C-reactive protein in pediatrics","volume":"16","author":"Jaye","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"10.1186\/2110-5820-2-32_bb0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00134-002-1209-6","article-title":"C-reactive protein: a valuable marker of sepsis","volume":"28","author":"Povoa","year":"2002","journal-title":"Intensive Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0115","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1172\/JCI116336","article-title":"Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease","volume":"91","author":"Vigushin","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1186\/2110-5820-2-32_bb0120","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00134-003-1664-8","article-title":"Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis","volume":"29","author":"Dahaba","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jcrc.2010.07.014","article-title":"Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: a cohort study","volume":"26","author":"Salluh","year":"2011","journal-title":"J Crit Care"},{"key":"10.1186\/2110-5820-2-32_bb0130","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/cc10242","article-title":"C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia","volume":"15","author":"Povoa","year":"2011","journal-title":"Crit Care"},{"key":"10.1186\/2110-5820-2-32_bb0135","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s001340000624","article-title":"Procalcitonin as a marker of the systemic inflammatory response to infection","volume":"26","author":"Reinhart","year":"2000","journal-title":"Intensive Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0883-9441(99)90005-9","article-title":"Katacalcin and calcitonin immunoreactivity in different types of leukocytes indicate intracellular procalcitonin content","volume":"14","author":"Oberhoffer","year":"1999","journal-title":"J Crit Care"},{"key":"10.1186\/2110-5820-2-32_bb0145","first-page":"1605","article-title":"Procalcitonin increase after endotoxin injection in normal subjects","volume":"79","author":"Dandona","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1186\/2110-5820-2-32_bb0150","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s001340050683","article-title":"Kinetics of procalcitonin in iatrogenic sepsis","volume":"24","author":"Brunkhorst","year":"1998","journal-title":"Intensive Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0155","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1086\/505394","article-title":"Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations","volume":"43","author":"Schuttrumpf","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1186\/2110-5820-2-32_bb0160","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/CCM.0b013e3181692966","article-title":"Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery","volume":"36","author":"Amour","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0165","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00134-009-1681-3","article-title":"Value of procalcitonin for diagnosis of early onset pneumonia in hypothermia-treated cardiac arrest patients","volume":"36","author":"Mongardon","year":"2010","journal-title":"Intensive Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0170","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/0310057X0203000302","article-title":"Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients","volume":"30","author":"Dahaba","year":"2002","journal-title":"Anaesth Intensive Care"},{"key":"10.1186\/2110-5820-2-32_bb0175","unstructured":"Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. The National Academies Press, Washington; 2010."},{"key":"10.1186\/2110-5820-2-32_bb0180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ajcp\/75.1.50","article-title":"An evaluation of a C-reactive protein assay using a rate immunonephelometric procedure","volume":"75","author":"Gill","year":"1981","journal-title":"Am J Clin Pathol"},{"key":"10.1186\/2110-5820-2-32_bb0185","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s001340000709","article-title":"Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children","volume":"27","author":"Enguix","year":"2001","journal-title":"Intensive Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0190","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/108155899704500911","article-title":"Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization","volume":"45","author":"Snider","year":"1997","journal-title":"J Investig Med"},{"key":"10.1186\/2110-5820-2-32_bb0195","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4414\/smw.2005.11169","article-title":"Procalcitonin in bacterial infections\u2013hype, hope, more or less?","volume":"135","author":"Christ-Crain","year":"2005","journal-title":"Swiss Med Wkly"},{"key":"10.1186\/2110-5820-2-32_bb0200","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1183\/09031936.00166106","article-title":"Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators","volume":"30","author":"Christ-Crain","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1186\/2110-5820-2-32_bb0205","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/eri.10.25","article-title":"Procalcitonin for guidance of antibiotic therapy","volume":"8","author":"Schuetz","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1186\/2110-5820-2-32_bb0210","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1164\/rccm.200708-1238OC","article-title":"Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial","volume":"177","author":"Nobre","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0215","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","article-title":"Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial","volume":"375","author":"Bouadma","year":"2010","journal-title":"Lancet"},{"key":"10.1186\/2110-5820-2-32_bb0220","first-page":"359","article-title":"Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery?","volume":"54","author":"Svoboda","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"10.1186\/2110-5820-2-32_bb0225","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00423-008-0432-1","article-title":"Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study","volume":"394","author":"Schroeder","year":"2009","journal-title":"Langenbecks Arch Surg"},{"key":"10.1186\/2110-5820-2-32_bb0230","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1183\/09031936.00053209","article-title":"Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study","volume":"34","author":"Stolz","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1186\/2110-5820-2-32_bb0235","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/cc7903","article-title":"Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial","volume":"13","author":"Hochreiter","year":"2009","journal-title":"Crit Care"},{"key":"10.1186\/2110-5820-2-32_bb0240","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1097\/CCM.0b013e31821e8791","article-title":"Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial","volume":"39","author":"Jensen","year":"2011","journal-title":"Crit Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0245","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1164\/rccm.200311-1577CP","article-title":"The ethical relevance of the standard of care in the design of clinical trials","volume":"169","author":"Miller","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0250","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1097\/01.CCM.0000239116.01855.61","article-title":"Procalcitonin increase in early identification of critically ill patients at high risk of mortality","volume":"34","author":"Jensen","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1186\/2110-5820-2-32_bb0255","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(10)60696-4","article-title":"Procalcitonin in intensive care units: the PRORATA trial","volume":"375","author":"Gibot","year":"2010","journal-title":"Lancet"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2110-5820-2-32.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2110-5820-2-32\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025016486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025016486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2110-5820-2-32.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:15:56Z","timestamp":1776669356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025016486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"alternative-id":["S2110582025016486"],"URL":"https:\/\/doi.org\/10.1186\/2110-5820-2-32","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/2110-5820-2-32","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 P\u00f3voa and Salluh; licensee Springer. 2012. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"32"}}